Mogamulizumab (Mechanism of Action)

In this article, we will discuss Mogamulizumab (Mechanism of Action). So, let’s get started.

Mechanism of Action

Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells.


Mogamulizumab-kpkc exposure-response relationships and the time course of
pharmacodynamics response are unknown.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.